Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00281528. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Study identification
- NCT ID
- NCT00281528
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2006 (Actual)
- Primary completion
- Jul 1, 2010 (Actual)
- Completion
- Mar 1, 2011 (Actual)
- Last update posted
- Nov 22, 2019
2006 – 2011
United States locations
- U.S. sites
- 39
- U.S. states
- 22
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Division of Hematology/Oncology University of Alabama at Birmingham | Birmingham | Alabama | — | — |
| Little Rock Hematology Oncology Associates | Little Rock | Arkansas | — | — |
| California Oncology of the Central Valley | Fresno | California | — | — |
| Glendale Memorial Hospital & Health Center | Glendale | California | — | — |
| Front Range Cancer Specialists | Fort Collins | Colorado | — | — |
| Oncology Associates of Bridgeport | Bridgeport | Connecticut | 06610 | — |
| Palm Beach Institute of Hematology and Oncology | Boynton Beach | Florida | — | — |
| Memorial Cancer Institute/Breast Cancer Center | Hollywood | Florida | 33021 | — |
| Florida Cancer Institute | Hudson | Florida | — | — |
| Hematology Oncology Associates | Lake Worth | Florida | — | — |
| Medical Specialist of the Palm Beaches, Inc | Lake Worth | Florida | — | — |
| Gulfcoast Oncology Associates | St. Petersburg | Florida | — | — |
| Peachtree Hematology & Oncology Associates | Atlanta | Georgia | — | — |
| Northwest Georgia Oncology Centers, PC | Marietta | Georgia | — | — |
| Center of Hope for Cancers and Blood | Stockbridge | Georgia | 30281 | — |
| Maine Center for Cancer Medicine & Blood Disorders | Scarborough | Maine | — | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | — | — |
| Harbor View Cancer Center | Baltimore | Maryland | — | — |
| Boston Medical Center Moakley Building, Solomont Center for Hematology & Medical Oncology | Boston | Massachusetts | — | — |
| North Shore Medical Cancer Center | Peabody | Massachusetts | 01960 | — |
| St. John's Mercy Medical Center | St Louis | Missouri | — | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | — | — |
| Drs. Forte, Schleidere, & Attas, PA | Englewood | New Jersey | — | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | — | — |
| Monmouth Medical Center | Long Branch | New Jersey | — | — |
| Rosewell Park Cancer Institute Elm & Carlton Carlton Building | Buffalo | New York | — | — |
| Beth Israel Comprehensive Cancer Center | New York | New York | — | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | — | — |
| NYU Clinical Cancer Center | New York | New York | — | — |
| Marion L. Shepard Cancer Center | Washington | North Carolina | — | — |
| Medical Oncology Aultman Hospital | Canton | Ohio | — | — |
| Cancer Centers of Southwest Oklahoma Research | Lawton | Oklahoma | — | — |
| Abington Hematology Oncology | Willow Grove | Pennsylvania | — | — |
| Family Cancer Center | Collierville | Tennessee | — | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | — | — |
| TX Oncology, PA | Austin | Texas | — | — |
| South Texas Oncology & Hematology Clinical Research Dept. | San Antonio | Texas | — | — |
| Virginia Commonwealth University Medical Oncology | Richmond | Virginia | — | — |
| Swedish Cancer Institute | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00281528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 22, 2019 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00281528 live on ClinicalTrials.gov.